DE602006005901D1 - NANDROLON-17ß-CARBONATE - Google Patents

NANDROLON-17ß-CARBONATE

Info

Publication number
DE602006005901D1
DE602006005901D1 DE602006005901T DE602006005901T DE602006005901D1 DE 602006005901 D1 DE602006005901 D1 DE 602006005901D1 DE 602006005901 T DE602006005901 T DE 602006005901T DE 602006005901 T DE602006005901 T DE 602006005901T DE 602006005901 D1 DE602006005901 D1 DE 602006005901D1
Authority
DE
Germany
Prior art keywords
alkyl
compounds
disclosed
bond
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006005901T
Other languages
German (de)
English (en)
Inventor
Richard P Blye
Hyun K Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE602006005901D1 publication Critical patent/DE602006005901D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006005901T 2005-02-04 2006-01-24 NANDROLON-17ß-CARBONATE Active DE602006005901D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65037605P 2005-02-04 2005-02-04
PCT/US2006/002436 WO2006083618A1 (en) 2005-02-04 2006-01-24 NANDROLONE 17ß-CARBONATES

Publications (1)

Publication Number Publication Date
DE602006005901D1 true DE602006005901D1 (de) 2009-05-07

Family

ID=36283873

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006005901T Active DE602006005901D1 (de) 2005-02-04 2006-01-24 NANDROLON-17ß-CARBONATE

Country Status (8)

Country Link
US (1) US7820642B2 (enExample)
EP (1) EP1846434B1 (enExample)
JP (1) JP5227593B2 (enExample)
AT (1) ATE426610T1 (enExample)
AU (1) AU2006211907B2 (enExample)
CA (1) CA2596884C (enExample)
DE (1) DE602006005901D1 (enExample)
WO (1) WO2006083618A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109575098B (zh) * 2019-01-18 2021-01-01 湖南成大生物科技有限公司 诺孕美特的合成方法
CN110128529B (zh) * 2019-04-11 2023-07-07 中国农业科学院兰州畜牧与兽药研究所 一种去甲睾酮人工抗原的合成方法
WO2021252761A2 (en) * 2020-06-11 2021-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056727A (en) * 1960-10-27 1962-10-02 Roussel Uclaf Cyclohexylcarbonates of steroids
FR1215M (fr) * 1961-03-28 1962-04-02 Roussel Uclaf S A Soc Nouveau médicament, notamment pour le traitement des troubles dus a une hyperestrogénie ou a une hypoandrogénie.
FR6576M (enExample) * 1965-10-11 1968-12-30
FR5913M (enExample) * 1965-12-02 1968-04-01
US3629244A (en) * 1966-01-21 1971-12-21 Roussel Uclaf 17beta-ethers of delta 4 9 11-gonatrienes and compositions containing them
US3523126A (en) * 1967-12-13 1970-08-04 Du Pont Testosterone and 19-nortestosterone(4'-methylbicyclo(2,2,2)octane - 1' - methyl)carbonate and selected derivatives
GB1291293A (en) * 1970-05-29 1972-10-04 Du Pont Steroid carbonates and their preparation
GB1355663A (en) * 1970-06-17 1974-06-05 Theramex 19-nortestosterone 17- -p-substituted phenoxy-acetates
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
AU4534593A (en) * 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5622944A (en) * 1992-06-12 1997-04-22 Affymax Technologies N.V. Testosterone prodrugs for improved drug delivery
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
EP1272196B1 (en) * 2000-03-31 2006-08-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha,11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use
US20030134831A1 (en) * 2002-01-16 2003-07-17 Roberts William J Bioavailable prodrugs of androgenic steroids and related method
US6740646B2 (en) * 2002-01-16 2004-05-25 Biotest Laboratories, Llc Bioavailable prodrugs of androgenic steroids and related method
US20030134828A1 (en) * 2002-01-16 2003-07-17 Roberts William J. Composition and method for increasing in vivo androgen concentration

Also Published As

Publication number Publication date
ATE426610T1 (de) 2009-04-15
AU2006211907B2 (en) 2011-09-08
JP5227593B2 (ja) 2013-07-03
EP1846434B1 (en) 2009-03-25
EP1846434A1 (en) 2007-10-24
WO2006083618A1 (en) 2006-08-10
US7820642B2 (en) 2010-10-26
CA2596884C (en) 2013-11-12
US20080167283A1 (en) 2008-07-10
AU2006211907A1 (en) 2006-08-10
CA2596884A1 (en) 2006-08-10
JP2008530007A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
MX2018011706A (es) Composicion farmaceutica de hormona esteroide.
CL2012002722A1 (es) Forma farmaceutica parenteral que libera un inhibidor de aromatasa tal como anastrozol y exemestano, y un gestageno tal como levonorgestrel y gestodeno; y su uso para el tratamiento simultaneo de endometriosis y para la anticoncepcion.
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
AR053292A1 (es) Un sistema de suministro para dos o mas componentes acivos como parte de una composicion comestible
MX2018011705A (es) Composicion farmaceutica de hormona esteroide.
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
PH12013500970B1 (en) Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance
DOP2009000148A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
PH12018501002A1 (en) Pheromone composition to stimulate reproduction in female suids and method of use
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
SG157415A1 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
AR063550A2 (es) Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad
MX2017014768A (es) Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.
MX382074B (es) Procedimientos de tratamiento o prevención de enfermedades relacionadas con estrógenos.
NZ744338A (en) Formulations and methods for controlling the reproductive cycle and ovulation
ECSP055629A (es) COMPOSICIÓN QUE CONTIENE UN ESTEROIDE 11ß-HALOGENADO ANDRÓGENO Y UN GESTÁGENO ASÍ COMO UN CONTRACEPTIVO MASCULINO SOBRE LA BASE DE ESTAS COMPOSICIONES
DE602006005901D1 (de) NANDROLON-17ß-CARBONATE
TN2009000358A1 (en) Pharmaceutical compositions comprising a calcilytic agent
MX391234B (es) Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas.
ATE528347T1 (de) Kautschukmischung
MX2020002684A (es) Composiciones topicas.
PE20091471A1 (es) Sistemas de administracion de drogas que contienen estradiol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition